Jan 12, 2021
Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI)
Dec 22, 2020
Servier Announces a Collaboration to Explore Immune Checkpoint Signaling in Cancer
Dec 21, 2020
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer
Dec 21, 2020
Servier to Acquire Agios Pharmaceuticals' Oncology Business
Dec 4, 2020
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Oct 12, 2020
Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™
Sep 24, 2020
Servier and MBC BioLabs Announce Winner of the 2020 Servier Golden Ticket
Mar 19, 2020
Coronavirus: Adapting our Approach to Continue to Serve our Patients
Dec 4, 2019
Servier Showcases Robust Presence at ASH 2019
Oct 1, 2019
Servier Acquires non-Hodgkin B-cell Lymphoma Treatment PIXUVRI® (pixantrone) from CTI BioPharma, Strengthening the Servier Oncology Portfolio
Jun 3, 2019
Servier and MBC BioLabs Announce Winner of the 2019 Servier Golden Ticket
May 29, 2019
Servier Showcases Robust Presence at ASCO 2019

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More